SCHEMBL17295705

SCHEMBL17295705

Clc1ccc(-c2cnco2)c(Br)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.53
IMPDH2 P12268 8/20 0.50
LTA4H P09960 1/20 0.45
GAA P10253 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
IMPDH1 P20839 4/20 0.42
AAK1 Q2M2I8 1/20 0.40
PTK2 Q05397 1/20 0.39
PKM P14618 2/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30702221 1.00 NOTUM (0.53) NOTUMIMPDH2LTA4HGAAMEN1
SCHEMBL14143141 0.81 NOTUM (0.55) NOTUMIMPDH2LTA4HGAAMEN1
SCHEMBL2427867 0.79 LMNA (0.53) IMPDH2GAAMEN1KMT2AIMPDH1
SCHEMBL6169923 0.79 IMPDH2 (0.60) NOTUMIMPDH2GAAMEN1KMT2A
SCHEMBL27330522 0.79 NOTUM (0.56) NOTUMIMPDH2LTA4HMEN1KMT2A
SCHEMBL2435029 0.77 IMPDH2 (0.45) NOTUMIMPDH2GAAMEN1KMT2A
SCHEMBL6920562 0.76 NOTUM (0.49) NOTUMIMPDH2LTA4HGAAMEN1
SCHEMBL2431842 0.76 IMPDH2 (0.47) IMPDH2GAAMEN1KMT2AIMPDH1
SCHEMBL2434236 0.76 IMPDH2 (0.47) IMPDH2GAAMEN1KMT2AIMPDH1
SCHEMBL6920127 0.76 NOTUM (0.49) NOTUMIMPDH2LTA4HMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282748-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2025-09-11 US disclosed
CN-113292539-B Substituted oxopyridine derivatives 拜耳制药股份公司 2023-12-22 CN disclosed
US-20230024752-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
US-20230024752-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-3368036-B1 MACROCYCLIC PYRIDINE-N-OXIDE DERIVATIVES AS FACTOR XIA INHIBITORS MERCK SHARP & DOHME LLC (US) 2022-07-20 EP disclosed
US-11180471-B2 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-11-23 US disclosed
US-11180471-B2 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-11-23 US disclosed
CN-113292539-A Substituted oxopyridine derivatives 拜耳制药股份公司 2021-08-24 CN disclosed
CN-108026072-B Substituted oxopyridine derivatives 拜耳制药股份公司 2021-08-17 CN disclosed
CN-108430471-B Factor XIa inhibitors 默沙东公司 2021-07-09 CN disclosed
US-9783530-B2 Factor Xla inhibitors MERCK SHARP & DOHME CORP. (US) 2017-10-10 US disclosed
US-9783530-B2 Factor Xla inhibitors MERCK SHARP & DOHME CORP. (US) 2017-10-10 US disclosed
US-20170197953-A1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-07-13 US disclosed
US-20170197953-A1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-07-13 US disclosed
US-20170197953-A1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-07-13 US disclosed
WO-2017074832-A1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-05-04 WO disclosed
EP-3148542-A1 FACTOR XIA INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-04-05 EP disclosed
WO-2016168098-A1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-10-20 WO disclosed
WO-2015183709-A1 FACTOR XIA INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-12-03 WO disclosed
WO-2015183709-A1 FACTOR XIA INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197953-A1 FACTOR XIa INHIBITORS F11, TFPI, F2 NOTUM 959/4885IMPDH2 4701/4885LTA4H 1646/4885
US-11180471-B2 Substituted oxopyridine derivatives OGFOD1, VASP, PNPO NOTUM 2289/4885IMPDH2 583/4885LTA4H 1287/4885
US-20250282748-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES OGFOD1, VASP, PNPO NOTUM 2289/4885IMPDH2 583/4885LTA4H 1287/4885
US-20230024752-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES OGFOD1, VASP, PNPO NOTUM 2289/4885IMPDH2 583/4885LTA4H 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.